The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective

被引：30
|
作者：
Hayward, Carl [1 ]
Banner, Nicholas R. [2 ]
Morley-Smith, Andrew [1 ]
Lyon, Alexander R. [1 ]
Harding, Sian E. [3 ]
机构：
[1] Royal Brompton Hosp, Cardiovasc Biomed Res Unit, London SW3 6NP, England
[2] Royal Brompton & Harefield NHS Trust, Harefield Hosp, Harefield UB9 6JH, Middx, England
[3] Univ London Imperial Coll Sci Technol & Med, London SW3 6NP, England
来源：
HUMAN GENE THERAPY | 2015年 / 26卷 / 05期
关键词：
SARCOPLASMIC-RETICULUM CA2+-ATPASE; SMOOTH-MUSCLE-CELLS; CALCIUM UP-REGULATION; NEUTRALIZING ANTIBODIES; DILATED CARDIOMYOPATHY; CARDIAC-FUNCTION; VENTRICULAR-ARRHYTHMIAS; MYOCARDIAL-INFARCTION; FAILING HUMAN; RAT MYOCYTES;
D O I：
10.1089/hum.2015.018
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.
引用
收藏
页码：293 / 304
页数：12
相关论文
共 50 条
  • [41] Model-specific selection of molecular targets for heart failure gene therapy
    Katz, Michael G.
    Fargnoli, Anthony S.
    Tomasulo, Catherine E.
    Pritchette, Louella A.
    Bridges, Charles R.
    JOURNAL OF GENE MEDICINE, 2011, 13 (10) : 573 - 586
  • [42] Growth hormone as a potential future therapy for congestive heart failure
    Fazio, S
    Cittadini, A
    Biondi, B
    Palmieri, EA
    Saccà, L
    CORONARY ARTERY DISEASE, 1999, 10 (06) : 383 - 388
  • [43] Cell therapy for heart disease: current status and future directions
    Kahlon, Arunpreet
    Vaidya, Gaurang
    Bolli, Roberto
    MINERVA CARDIOANGIOLOGICA, 2018, 66 (03): : 273 - 291
  • [44] Statin Therapy and Clinical Outcomes in Heart Failure: A Propensity-Matched Analysis
    Ouzounian, Maral
    Tu, Jack V.
    Austin, Peter C.
    Chong, Alice
    Liu, Peter P.
    Lee, Douglas S.
    JOURNAL OF CARDIAC FAILURE, 2009, 15 (03) : 241 - 248
  • [45] Current status of cell-based therapy for heart failure
    Jakob P.
    Landmesser U.
    Current Heart Failure Reports, 2013, 10 (2) : 165 - 176
  • [46] Mind the Gap: Current Challenges and Future State of Heart Failure Care
    McDonald, Michael A.
    Ashley, Euan A.
    Fedak, Paul W. M.
    Hawkins, Nathaniel
    Januzzi, James L.
    McMurray, John J. V.
    Parikh, Victoria N.
    Rao, Vivek
    Svystonyuk, Daniyil
    Teerlink, John R.
    Virani, Sean
    CANADIAN JOURNAL OF CARDIOLOGY, 2017, 33 (11) : 1434 - 1449
  • [47] Surgical Treatment of Heart Failure: current repair strategies and future directions
    Maltais, S.
    Perrault, L. P.
    NEW HORIZONS IN CARDIOVASCULAR DISEASES, 2010, : 169 - 175
  • [48] S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials
    Rohde, David
    Brinks, Henriette
    Ritterhoff, Julia
    Qui, Gang
    Ren, Shumei
    Most, Patrick
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 50 (05) : 777 - 784
  • [49] Barriers in Heart Failure Gene Therapy and Approaches to Overcome Them
    Ravichandran, Anjali J.
    Romeo, Francisco J.
    Mazurek, Renata
    Ishikawa, Kiyotake
    HEART LUNG AND CIRCULATION, 2023, 32 (07) : 780 - 789
  • [50] Recent findings into the potential of gene therapy to reverse heart failure
    Pleger, Sven T.
    Most, Patrick
    Koch, Walter J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (12) : 1781 - 1784
12345